New Frontier Health Corporation (NFH)

Common Stock

11.95  +0.03 (+0.25%)

After market: 11.99 +0.04 (+0.33%)

Fundamental Rating

1

NFH gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 117 industry peers in the Health Care Providers & Services industry. NFH has a bad profitability rating. Also its financial health evaluation is rather negative. NFH has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

NFH had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -3.77%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -3.47%
PM (TTM) -22.37%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

NFH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, NFH has an improved debt to assets ratio.

2.2 Solvency

NFH has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.05 indicates that NFH should not have too much problems paying its short term obligations.
A Quick Ratio of 0.96 indicates that NFH may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.96

3

3. Growth

3.1 Past

NFH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -115.35%.
NFH shows a decrease in Revenue. In the last year, the revenue decreased by -7.71%.
EPS 1Y (TTM)-115.35%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-61.96%
Revenue 1Y (TTM)-7.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-73.3%

3.2 Future

The Earnings Per Share is expected to grow by 32.17% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 19.14% on average over the next years. This is quite good.
EPS Next Y82.35%
EPS Next 2Y48.63%
EPS Next 3Y36.73%
EPS Next 5Y32.17%
Revenue Next Year30.43%
Revenue Next 2Y23.9%
Revenue Next 3Y21.16%
Revenue Next 5Y19.14%

3.3 Evolution

1

4. Valuation

4.1 Price/Earnings Ratio

NFH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NFH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 32.99

4.3 Compensation for Growth

NFH's earnings are expected to grow with 36.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.63%
EPS Next 3Y36.73%

0

5. Dividend

5.1 Amount

No dividends for NFH!.
Industry RankSector Rank
Dividend Yield N/A

New Frontier Health Corporation

NYSE:NFH (1/26/2022, 7:47:10 PM)

After market: 11.99 +0.04 (+0.33%)

11.95

+0.03 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.58B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.77%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -3.47%
PM (TTM) -22.37%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.05
Quick Ratio 0.96
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-115.35%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y82.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.71%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y